Caris Life Sciences, Inc. CAI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 26.99% | 45.38% | 78.78% | 125.44% | 81.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.99% | 45.38% | 78.78% | 125.44% | 81.31% |
| Cost of Revenue | 34.25% | 24.22% | 17.19% | 21.77% | 8.35% |
| Gross Profit | 23.58% | 57.98% | 147.71% | 207.93% | 202.72% |
| SG&A Expenses | 38.49% | 12.83% | 13.92% | 23.44% | 33.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.01% | 18.76% | 17.91% | 22.47% | 19.35% |
| Operating Income | -40.82% | 249.68% | 109.11% | 338.65% | 73.16% |
| Income Before Tax | -30.63% | 99.14% | 99.37% | 321.82% | -8.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.31% | 99.11% | 99.50% | 321.82% | -8.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.31% | 99.11% | 99.50% | 321.82% | -8.47% |
| EBIT | -40.82% | 249.68% | 109.11% | 338.65% | 73.16% |
| EBITDA | -30.90% | 388.98% | 120.33% | 431.32% | 79.10% |
| EPS Basic | -37.70% | 99.97% | 99.95% | 116.72% | -213.88% |
| Normalized Basic EPS | -31.17% | 110.49% | 99.92% | 128.71% | 55.66% |
| EPS Diluted | -37.50% | 99.97% | 99.95% | 115.98% | -213.88% |
| Normalized Diluted EPS | -30.27% | 110.49% | 99.92% | 127.35% | 55.66% |
| Average Basic Shares Outstanding | 0.64% | 335.76% | 693.20% | 691.44% | 83.54% |
| Average Diluted Shares Outstanding | -0.70% | 335.76% | 693.20% | 730.35% | 83.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |